Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,301.21 +54.53 (+1.04%) Dow
39,834.86 +276.75 (+0.70%) Nasdaq
16,729.48 +218.30 (+1.32%) Bitcoin USD
65,399.87 +4,112.71 (+6.71%) CMC Crypto 200
1,378.58 +110.63 (+8.73%)
BioMarin Pharmaceutical Inc. (0HNC.L)
| Previous close | 79.67 |
| Open | 80.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 80.14 - 80.85 |
| 52-week range | 76.29 - 99.65 |
| Volume | |
| Avg. volume | 5,967 |
| Market cap | 147.247M |
| Beta (5Y monthly) | 0.34 |
| PE ratio (TTM) | 3.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President, and Chief Executive Officer of BioMarin will present at the BofA Securities 2024 Healthcare Conference on Wednesday, May 15, 2024, at 10:00am PT / 1:00pm ET, in Las Vegas, Nevada.
- PR Newswire
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive new data supporting the safety and efficacy of VOXZOGO® (vosoritide) in children with achondroplasia, as well as positive data for investigational uses in growth-related conditions, including idiopathic short stature (ISS) and Noonan syndrome, were presented at the 2024 Pediatric Endocrine Society (PES) Annual Meeting in Chicago, May 2-5, 2024. Researchers also presented results from additional studies highlighting the medicine'
- PR Newswire
BioMarin Reports Record Financial Results for the First Quarter 2024
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the quarter ended March 31, 2024.
